Blalock Williams’s Vertex Pharmaceuticals VRTX Stock Holding History

Blalock Williams’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-444	Closed	-$202K	–	156
2025 Q4	$202K	Buy	+444	New	+$191K	0.16%	135

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Blalock Williams's VRTX Position: Q1 2026 in Review

Blalock Williams sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 444 shares — an estimated $202K sold.

Blalock Williams first reported a position in VRTX in Q4 2025 and held it in 1 quarter. The position peaked at $202K in Q4 2025. 1,689 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Blalock Williams reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Blalock Williams sold 444 Vertex Pharmaceuticals shares in Q1 2026, an estimated $202K.
Blalock Williams first reported a position in Vertex Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Blalock Williams's Vertex Pharmaceuticals position peaked at $202K in Q4 2025.
1,689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Blalock Williams's 13F filing for Q1 2026, filed 14 May 2026.